In this study, we propose a novel approach to enhancing transfer learning by optimizing data selection through deep learning techniques and corresponding innovative learning strategies. This method is particularly beneficial when the available dataset has reached its limit and cannot be further expanded. Our approach focuses on maximizing the use of existing data to improve learning outcomes which offers an effective solution for data-limited applications in medical imaging classification. The proposed method consists of two stages. In the first stage, an original network performs the initial classification. When the original network exhibits low confidence in its predictions, ambiguous classifications are passed to a secondary decision-making step involving a newly trained network, referred to as the True network. The True network shares the same architecture as the original network but is trained on a subset of the original dataset that is selected based on consensus among multiple independent networks. It is then used to verify the classification results of the original network, identifying and correcting any misclassified images. To evaluate the effectiveness of our approach, we conducted experiments using thyroid nodule ultrasound images with the ResNet101 and Vision Transformer architectures along with eleven other pre-trained neural networks. The proposed method led to performance improvements across all five key metrics, accuracy, sensitivity, specificity, F1-score, and AUC, compared to using only the original or True networks in ResNet101. Additionally, the True network showed strong performance when applied to the Vision Transformer and similar enhancements were observed across multiple convolutional neural network architectures. Furthermore, to assess the robustness and adaptability of our method across different medical imaging modalities, we applied it to dermoscopic images and observed similar performance enhancements. These results provide evidence of the effectiveness of our approach in improving transfer learning-based medical image classification without requiring additional training data.

High-grade gliomas, particularly glioblastoma (MeSH:Glioblastoma), are among the most aggressive and lethal central nervous system tumors, necessitating advanced diagnostic and prognostic strategies. This systematic review and epistemic meta-analysis explore the integration of Artificial Intelligence (AI) and Radiomics Inter-field (AIRI) to enhance predictive modeling for tumor progression. A comprehensive literature search identified 19 high-quality studies, which were analyzed to evaluate radiomic features and machine learning models in predicting overall survival (OS) and progression-free survival (PFS). Key findings highlight the predictive strength of specific MRI-derived radiomic features such as log-filter and Gabor textures and the superior performance of Support Vector Machines (SVM) and Random Forest (RF) models, achieving high accuracy and AUC scores (e.g., 98% AUC and 98.7% accuracy for OS). This research demonstrates the current state of the AIRI field and shows that current articles report their results with different performance indicators and metrics, making outcomes heterogenous and hard to integrate knowledge. Additionally, it was explored that today some articles use biased methodologies. This study proposes a structured AIRI development roadmap and guidelines, to avoid bias and make results comparable, emphasizing standardized feature extraction and AI model training to improve reproducibility across clinical settings. By advancing precision medicine, AIRI integration has the potential to refine clinical decision-making and enhance patient outcomes.

Low back pain (LBP) is a prevalent pain condition whose persistence can lead to changes in the brain regions responsible for sensory, cognitive, attentional, and emotional processing. Previous neuroimaging studies have identified various structural and functional abnormalities in patients with LBP; however, how the static and dynamic large-scale functional network connectivity (FNC) of the brain is affected in these patients remains unclear. Forty-one patients with chronic low back pain (cLBP) and 42 healthy controls underwent resting-state functional MRI scanning. The independent component analysis method was employed to extract the resting-state networks. Subsequently, we calculate and compare between groups for static intra- and inter-network functional connectivity. In addition, we investigated the differences between dynamic functional network connectivity and dynamic temporal metrics between cLBP patients and healthy controls. Finally, we tried to distinguish cLBP patients from healthy controls by support vector machine method. The results showed that significant reductions in functional connectivity within the network were found within the DMN,DAN, and ECN in cLBP patients. Significant between-group differences were also found in static FNC and in each state of dynamic FNC. In addition, in terms of dynamic temporal metrics, fraction time and mean dwell time were significantly altered in cLBP patients. In conclusion, our study suggests the existence of static and dynamic large-scale brain network alterations in patients with cLBP. The findings provide insights into the neural mechanisms underlying various brain function abnormalities and altered pain experiences in patients with cLBP.

Medical images occupy the largest part of the existing medical information and dealing with them is challenging not only in terms of management but also in terms of interpretation and analysis. Hence, analyzing, understanding, and classifying them, becomes a very expensive and time-consuming task, especially if performed manually. Deep learning is considered a good solution for image classification, segmentation, and transfer learning tasks since it offers a large number of algorithms to solve such complex problems. PRISMA-ScR guidelines have been followed to conduct the scoping review with the aim of exploring how deep learning is being used to classify a broad spectrum of diseases diagnosed using an X-ray, MRI, or Ultrasound image modality.Findings contribute to the existing research by outlining the characteristics of the adopted datasets and the preprocessing or augmentation techniques applied to them. The authors summarized all relevant studies based on the deep learning models used and the accuracy achieved for classification. Whenever possible, they included details about the hardware and software configurations, as well as the architectural components of the models employed. Moreover, the models that achieved the highest accuracy in disease classification were highlighted, along with their strengths. The authors also discussed the limitations of the current approaches and proposed future directions for medical image classification.

Timely intervention and improved prognosis for breast cancer patients rely on early metastasis risk detection and accurate treatment predictions. This study introduces an advanced multimodal MRI and AI-driven 3D deep learning model, termed the 3D-MMR-model, designed to predict recurrence risk in non-metastatic breast cancer patients. We conducted a multicenter study involving 1199 non-metastatic breast cancer patients from four institutions in China, with comprehensive MRI and clinical data retrospectively collected. Our model employed multimodal-data fusion, utilizing contrast-enhanced T1-weighted imaging (T1 + C) and T2-weighted imaging (T2WI) volumes, processed through a modified 3D-UNet for tumor segmentation and a DenseNet121-based architecture for disease-free survival (DFS) prediction. Additionally, we performed RNA-seq analysis to delve further into the relationship between concentrated hotspots within the tumor region and the tumor microenvironment. The 3D-MR-model demonstrated superior predictive performance, with time-dependent ROC analysis yielding AUC values of 0.90, 0.89, and 0.88 for 2-, 3-, and 4-year DFS predictions, respectively, in the training cohort. External validation cohorts corroborated these findings, highlighting the model's robustness across diverse clinical settings. Integration of clinicopathological features further enhanced the model's accuracy, with a multimodal approach significantly improving risk stratification and decision-making in clinical practice. Visualization techniques provided insights into the decision-making process, correlating predictions with tumor microenvironment characteristics. In summary, the 3D-MMR-model represents a significant advancement in breast cancer prognosis, combining cutting-edge AI technology with multimodal imaging to deliver precise and clinically relevant predictions of recurrence risk. This innovative approach holds promise for enhancing patient outcomes and guiding individualized treatment plans in breast cancer care.

Timely intervention for Alzheimers disease (AD) requires early detection. The development of immunotherapies targeting amyloid-beta and tau underscores the need for accessible, time-efficient biomarkers for early diagnosis. Here, we directly applied our previously developed MRI-based deep learning model for AD to the large Chinese SILCODE cohort (722 participants, 1,105 brain MRI scans). The model -- initially trained on North American data -- demonstrated robust cross-ethnic generalization, without any retraining or fine-tuning, achieving an AUC of 91.3% in AD classification with a sensitivity of 95.2%. It successfully identified 86.7% of individuals at risk of AD progression more than 5 years in advance. Individuals identified as high-risk exhibited significantly shorter median progression times. By integrating an interpretable deep learning brain risk map approach, we identified AD brain subtypes, including an MCI subtype associated with rapid cognitive decline. The models risk scores showed significant correlations with cognitive measures and plasma biomarkers, such as tau proteins and neurofilament light chain (NfL). These findings underscore the exceptional generalizability and clinical utility of MRI-based deep learning models, especially in large and diverse populations, offering valuable tools for early therapeutic intervention. The model has been made open-source and deployed to a free online website for AD risk prediction, to assist in early screening and intervention.

A three-dimensional convolutional neural network was developed to classify T1-weighted brain MRI scans as healthy or Alzheimer. The network comprises 3D convolution, pooling, batch normalization, dense ReLU layers, and a sigmoid output. Using stochastic noise injection and five-fold cross-validation, the model achieved test set accuracy of 0.912 and area under the ROC curve of 0.961, an improvement of approximately 0.027 over resizing alone. Sensitivity and specificity both exceeded 0.90. These results align with prior work reporting up to 0.10 gain via synthetic augmentation. The findings demonstrate the effectiveness of simple augmentation for 3D MRI classification and motivate future exploration of advanced augmentation methods and architectures such as 3D U-Net and vision transformers.

Alzheimers Disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss. In 2024, in the US alone, it affected approximately 1 in 9 people aged 65 and older, equivalent to 6.9 million individuals. Early detection and accurate AD diagnosis are crucial for improving patient outcomes. Magnetic resonance imaging (MRI) has emerged as a valuable tool for examining brain structure and identifying potential AD biomarkers. This study performs predictive analyses by employing machine learning techniques to identify key brain regions associated with AD using numerical data derived from anatomical MRI scans, going beyond standard statistical methods. Using the Random Forest Algorithm, we achieved 92.87% accuracy in detecting AD from Mild Cognitive Impairment and Cognitive Normals. Subgroup analyses across nine sex- and age-based cohorts (69-76 years, 77-84 years, and unified 69-84 years) revealed the hippocampus, amygdala, and entorhinal cortex as consistent top-rank predictors. These regions showed distinct volume reductions across age and sex groups, reflecting distinct age- and sex-related neuroanatomical patterns. For instance, younger males and females (aged 69-76) exhibited volume decreases in the right hippocampus, suggesting its importance in the early stages of AD. Older males (77-84) showed substantial volume decreases in the left inferior temporal cortex. Additionally, the left middle temporal cortex showed decreased volume in females, suggesting a potential female-specific influence, while the right entorhinal cortex may have a male-specific impact. These age-specific sex differences could inform clinical research and treatment strategies, aiding in identifying neuroanatomical markers and therapeutic targets for future clinical interventions.

Performance comparisons are fundamental in medical imaging Artificial Intelligence (AI) research, often driving claims of superiority based on relative improvements in common performance metrics. However, such claims frequently rely solely on empirical mean performance. In this paper, we investigate whether newly proposed methods genuinely outperform the state of the art by analyzing a representative cohort of medical imaging papers. We quantify the probability of false claims based on a Bayesian approach that leverages reported results alongside empirically estimated model congruence to estimate whether the relative ranking of methods is likely to have occurred by chance. According to our results, the majority (>80%) of papers claims outperformance when introducing a new method. Our analysis further revealed a high probability (>5%) of false outperformance claims in 86% of classification papers and 53% of segmentation papers. These findings highlight a critical flaw in current benchmarking practices: claims of outperformance in medical imaging AI are frequently unsubstantiated, posing a risk of misdirecting future research efforts.

Magnetic Resonance Imaging (MRI) is the gold standard in countless diagnostic procedures, yet hardware complexity, long scans, and cost preclude rapid screening and point-of-care use. We introduce Imageless Magnetic Resonance Diagnosis (IMRD), a framework that bypasses k-space sampling and image reconstruction by analyzing raw one-dimensional MR signals. We identify potentially impactful embodiments where IMRD requires only optimized pulse sequences for time-domain contrast, minimal low-field hardware, and pattern recognition algorithms to answer clinical closed queries and quantify lesion burden. As a proof of concept, we simulate multiple sclerosis lesions in silico within brain phantoms and deploy two extremely fast protocols (approximately 3 s), with and without spatial information. A 1D convolutional neural network achieves AUC close to 0.95 for lesion detection and R2 close to 0.99 for volume estimation. We also perform robustness tests under reduced signal-to-noise ratio, partial signal omission, and relaxation-time variability. By reframing MR signals as direct diagnostic metrics, IMRD paves the way for fast, low-cost MR screening and monitoring in resource-limited environments.